Biotech · Public company · Princeton, NJ, US
Soligenix, Inc.
Ticker SNGX · SEC CIK 0000812796
Track this companyFree. Adds Soligenix, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials70 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline6
- HypericinPhase 3 · CTCL/ Mycosis FungoidesClinicalTrials.gov · fetched Nov 12, 2026
- SGX301 (synthetic hypericin)Phase 3 · Cutaneous T-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- SGX942Phase 3 · Squamous Cell Carcinoma of the Oral Cavity and OropharynxClinicalTrials.gov · fetched Nov 12, 2026
- HypericinPhase 2 · Cutaneous T-Cell Lymphoma/Mycosis FungoidesClinicalTrials.gov · fetched Nov 12, 2026
- HypericinPhase 2 · PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Mechlorethamine Topical GelPhase 2 · Cutaneous T-Cell Lymphoma/Mycosis FungoidesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCLPHASE3 · TERMINATED · started Jan 7, 2025ClinicalTrials.gov NCT06470451 · fetched Nov 12, 2026
- HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCLPHASE2 · COMPLETED · started Dec 5, 2023ClinicalTrials.gov NCT06149247 · fetched Nov 12, 2026
- Treatment of Mycosis Fungoides With Hypericin Ointment and Visible LightPHASE2 · COMPLETED · started Aug 21, 2023ClinicalTrials.gov NCT05872854 · fetched Nov 12, 2026
- Topical SGX302 for Mild-to-Moderate PsoriasisPHASE2 · COMPLETED · started Dec 14, 2022ClinicalTrials.gov NCT05442190 · fetched Nov 12, 2026
- PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell LymphomaPHASE2 · COMPLETED · started May 9, 2022ClinicalTrials.gov NCT05380635 · fetched Nov 12, 2026
- DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck CancerPHASE3 · COMPLETED · started Dec 4, 2017ClinicalTrials.gov NCT03237325 · fetched Nov 12, 2026
- FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)PHASE3 · COMPLETED · started Dec 1, 2015ClinicalTrials.gov NCT02448381 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 21, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 26, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 28, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 28, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 12, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jan 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 18, 2025 · fetched Nov 12, 2026